Terns Pharmaceuticals (TERN) Competitors

Evotec (NASDAQ:EVO) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.

Which has more volatility and risk, EVO or TERN?

Evotec has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500.

Is EVO or TERN more profitable?

Evotec's return on equity of 0.00% beat Terns Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	N/A	N/A	N/A
Terns Pharmaceuticals	N/A	-32.76%	-31.33%

Which has higher earnings and valuation, EVO or TERN?

Terns Pharmaceuticals has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$845.74M	1.89	-$90.82M	N/A	N/A
Terns Pharmaceuticals	N/A	N/A	-$90.21M	-$1.18	-3.78

Does the MarketBeat Community believe in EVO or TERN?

Terns Pharmaceuticals received 36 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 60.87% of users gave Terns Pharmaceuticals an outperform vote while only 54.55% of users gave Evotec an outperform vote.

Company	Underperform	Outperform
Evotec	Outperform Votes 6 54.55%	Underperform Votes 5 45.45%
Terns Pharmaceuticals	Outperform Votes 42 60.87%	Underperform Votes 27 39.13%

Do analysts recommend EVO or TERN?

Evotec presently has a consensus price target of $5.93, suggesting a potential upside of 31.27%. Terns Pharmaceuticals has a consensus price target of $18.30, suggesting a potential upside of 310.31%. Given Terns Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Evotec.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Terns Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Do institutionals & insiders believe in EVO or TERN?

5.8% of Evotec shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media favor EVO or TERN?

In the previous week, Evotec had 1 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 4 mentions for Evotec and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.76 beat Evotec's score of 0.71 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Terns Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Terns Pharmaceuticals beats Evotec on 9 of the 14 factors compared between the two stocks.